Merck & Co., Inc. (MRK)

Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NYSE
Market cap: $327.41B
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Latest financial period: September 30, 2026
Filed with the SEC: November 4, 2026
Estimated earnings date: Not available
Profit #590 of 1422 companies
| | Sep 26 | Jun 26 | Mar 26 | Dec 25 |
|---|
| ROE/ROA | 59.4% | 60.4% | 78.3% | 89.3% |
Growth #1014 of 1422 companies
Payout #558 of 1422 companies
Safety #545 of 1422 companies
Price #1019 of 1422 companies